GSK plc (NYSE:GSK) Shares Sold by Drucker Wealth 3.0 LLC

Drucker Wealth 3.0 LLC decreased its holdings in GSK plc (NYSE:GSK - Free Report) by 17.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,665 shares of the pharmaceutical company's stock after selling 15,001 shares during the quarter. Drucker Wealth 3.0 LLC's holdings in GSK were worth $2,322,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Dorsey & Whitney Trust CO LLC grew its holdings in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares during the period. Northwest Bank & Trust Co lifted its stake in shares of GSK by 1.3% in the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after purchasing an additional 289 shares in the last quarter. GC Wealth Management RIA LLC lifted its stake in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after purchasing an additional 353 shares in the last quarter. Jacobi Capital Management LLC lifted its stake in shares of GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC lifted its stake in shares of GSK by 3.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after purchasing an additional 407 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GSK shares. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, Morgan Stanley assumed coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Stock Down 0.6%

GSK stock traded down $0.22 during midday trading on Wednesday, hitting $39.22. 4,220,823 shares of the company were exchanged, compared to its average volume of 4,828,479. The company's fifty day moving average price is $37.26 and its 200-day moving average price is $36.06. The company has a market cap of $80.92 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.01.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the company posted $0.43 EPS. GSK's quarterly revenue was up 2.1% on a year-over-year basis. On average, research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.30%. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio is presently 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.